A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
Completed · Phase 2 · Has a placebo group
Conditions studied: Obesity or Overweight
In brief
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
Key facts
- Study ID
- NCT06595238
- Run by
- AstraZeneca
- People needed
- 262
- Starts
- 2024-10-01
- Expected to finish
- 2025-12-03
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
You may not qualify if…
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
- History of type 1 diabetes mellitus or T2DM
Where it is running
- Research Site — Mobile, Alabama, United States
- Research Site — Phoenix, Arizona, United States
- Research Site — Long Beach, California, United States
- Research Site — Hialeah, Florida, United States
- Research Site — Largo, Florida, United States
- Research Site — Orlando, Florida, United States
- Research Site — Tampa, Florida, United States
- Research Site — Woodstock, Georgia, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Lutherville-Timonium, Maryland, United States
- Research Site — Gulfport, Mississippi, United States
- Research Site — Ridgeland, Mississippi, United States
- Research Site — Kansas City, Missouri, United States
- Research Site — Omaha, Nebraska, United States
- Research Site — Portsmouth, New Hampshire, United States
- Research Site — Statesville, North Carolina, United States
- Research Site — North Charleston, South Carolina, United States
- Research Site — Knoxville, Tennessee, United States
- Research Site — Austin, Texas, United States
- Research Site — Dallas, Texas, United States
- Research Site — Port Arthur, Texas, United States
- Research Site — San Antonio, Texas, United States
- Research Site — San Antonio, Texas, United States
- Research Site — Heidelberg, Australia
- Research Site — Maroochydore, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.